ClinicalTrials.gg
CompletedNCT04470128Updated Feb 21, 2023

A Study Evaluating the Efficacy and Safety of HSK21542 Injection for Analgesia in Subjects Undergoing Colonoscopy

A Phase 2 interventional study of Stage I: HSK21542 0.5 μg/kg and Stage I: HSK21542 1 μg/kg in Analgesia, sponsored by Haisco Pharmaceutical Group Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-02-21.

Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a multi-center, randomized, two-stage, phase II clinical study .The main objective is to evaluate the safety and tolerability of HSK21542 injection for analgesia in patients undergoing colonoscopy, and, combining the pharmacodynamic (PD) and pharmacokinetic (PK) characteristics

02

Conditions studied

  • Analgesia
03

In context

Lead sponsor

Haisco Pharmaceutical Group Co., Ltd. is the lead sponsor of 118 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects undergoing diagnostic and/or therapeutic colonoscopy with an estimated operation duration of 15-45 min;
  2. Aged ≥ 18 and ≤ 75 years old, with no restriction on gender;
  3. (ASA) Class I-II;
  4. ≥ 18 kg/m\^2 and ≤ 30 kg/m\^2;
  5. During screening and at baseline: respiratory rate ≥ 10 and ≤ 24 bpm; SpO2 ≥ 95% during inhalation; SBP ≥ 90 mmHg; DBP ≥ 50 mmHg; HR ≥ 50 and ≤ 100 bpm;
  6. Subjects with intelligence and consciousness sufficient enough for cooperating with the study;
  7. Capable of understanding the procedure and method of this study, willing to sign an form and to complete this study in strict accordance with the study protocol.

Exclusion criteria

Exclusion Criteria:

  1. Patients having to deep sedation/general anesthesia or a history of past sedation/anesthesia accidents;
  2. Patients with past history of allergy or contraindications to opioids, their rescue medications, and propofol;
  3. Medical history or evidence of any of the following prior to screening/at baseline, which may increase sedation/anesthesia risk:

    1. History of cardiovascular diseases: uncontrolled hypertension (systolic blood pressure [SBP] ≥ 170 mmHg and/or diastolic blood pressure [DBP] ≥ 105 mmHg without treatment, or SBP > 160 mmHg and/or DBP > 100 mmHg after antihypertensive treatment), severe arrhythmia, heart failure, Adams-Stokes syndrome, (NYHA) Class ≥ III, severe superior vena cava syndrome, pericardial effusion, acute myocardial ischemia, unstable angina, myocardial infarction within 6 months before screening, history of tachycardia/bradycardia requiring medical treatment, II-III degree atrioventricular block (excluding patients with pacemakers);
    2. History of respiratory system disorders: respiratory insufficiency, history of obstructive pulmonary disease, history of bronchospasm requiring treatment within 3 months prior to screening, acute respiratory tract infection with obvious symptoms such as fever, wheezing, nasal obstruction, and cough within 1 week prior to baseline;
    3. History of neurological and psychiatric disorders: craniocerebral injury, possible convulsions, myoclonus, intracranial hypertension, cerebral aneurysms, history of cerebrovascular accidents; schizophrenia, mania, insanity, long-term use of psychotropic drugs, and history of cognitive dysfunction; history of depression, anxiety, and epilepsy, etc.;
    4. History of gastrointestinal disorders: gastrointestinal retention, active hemorrhage, or conditions that may lead to reflux and aspiration;
    5. History of alcohol abuse within 3 months prior to screening, with abuse defined as average of > 2 units of alcohol per day (1 unit = 360 mL beer or 45 mL liquor with 40% alcohol or 150 mL wine);
    6. History of drug abuse within 3 months prior to screening;
    7. History of blood donation or blood loss of ≥ 400 mL within 3 months prior to screening;
  4. Patients with the following airway management risks:

    1. Asthma history, and stridor;
    2. Sleep apnea syndrome;
    3. History or family history of malignant hyperthermia;
    4. History of failed tracheal intubation;
    5. Judged by the investigator to have difficult airway or judged as difficult tracheal intubation (modified Mallampati class IV) at screening;
  5. In receipt of any one of the following medications or treatments at screening:

    1. A time between the last use of opioid and non-opioid (such as paracetamol, aspirin [daily dose > 100 mg], indomethacin, diclofenac, parecoxib sodium, and other non-steroidal anti-inflammatory drugs) analgesics and randomization of shorter than 5 half-lives of the drug or the duration of the drug's efficacy (whichever is longer);
    2. Longer than 10 days of continuous use of opioid analgesics for any reason within 3 months prior to screening;
    3. Use of drugs that affect the analgesic effect within 14 days before randomization, including but not limited to: sedative-hypnotics (benzodiazepines [triazolam, diazepam, and midazolam] and non-benzodiazepines [zolpidem, zopiclone, zaleplon]), sedative-anesthetics (sevoflurane, nitrous oxide, ketamine, and etomidate), (dexamethasone hydrochloride and methylprednisolone), antiepileptics (carbamazepine and sodium valproate), anxiolytics (chlordiazepoxide), antidepressants (imipramine and amitriptyline), and Chinese herbal medicines or Chinese patent medicines with analgesic and sedative effects;
    4. A time between randomization and the last use of diuretics and compound drugs containing diuretics of shorter than 5 half-lives of the drug or the duration of the drug's efficacy (whichever is longer);
  6. Patient whose laboratory parameters measured at screening reach the following criteria and are verified through reexamination:

    1. WBC \< 3.0 × 10\^9/L;
    2. count \< 80 × 10\^9/L;
    3. \< 80 g/L;
    4. > 1.5 × ;
    5. Activated partial thromboplastin time > 1.5 × ULN;
    6. (ALT) and/or aspartate aminotransferase (AST) ≥ 2 × ULN;
    7. Total > 1.5 × ULN;
    8. Blood creatinine > 1.5 × ULN;
  7. Having participated in other drug clinical trials within 3 months prior to screening (defined as having received product or placebo);
  8. Pregnant or breastfeeding females: women or men of who are unwilling to use during the trial; subjects who are planning pregnancy within 3 months after the trial (including male subjects);
  9. Subject judged by the investigator to have any other factors unsuitable for involvement in the study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    Stage I: HSK21542 0.5 μg/kg

    intravenous injection

    Drug: Stage I: HSK21542 0.5 μg/kg

  • Experimental
    Stage I: HSK21542 1 μg/kg

    intravenous injection

    Drug: Stage I: HSK21542 1 μg/kg

  • Experimental
    Stage II : HSK21542 0.5 μg/kg

    intravenous injection

    Drug: HSK21542 0.5 μg/kg

  • Experimental
    Stage II : HSK21542 1 μg/kg

    intravenous injection

    Drug: HSK21542 1 μg/kg

  • Experimental
    Stage II : HSK21542 2 μg/kg

    intravenous injection

    Drug: HSK21542 2 μg/kg

  • Placebo comparator
    Stage II : placebo

    intravenous injection

    Drug: Placebo

Interventions

  • DrugStage I: HSK21542 0.5 μg/kg

    intravenous injection

  • DrugStage I: HSK21542 1 μg/kg

    intravenous injection

  • DrugHSK21542 0.5 μg/kg

    intravenous injection

  • DrugHSK21542 1 μg/kg

    Drug page: Anrikefon

    intravenous injection

  • DrugHSK21542 2 μg/kg

    intravenous injection

  • DrugPlacebo

    intravenous injection

06

What researchers measure

Primary outcomes

  1. BPS-NI score>3 did not reach the proportion

    the proportion of subjects with BPS-NI score\>3 did not appear from the beginning of insertion of colonoscopy to the removal of colonoscopy

    Time frame: From administration until 24 hours after administration

Secondary outcomes

  1. Number of occurrences of BPS-NI score of > 3

    The ratio of subjects with BPS-NI scores of \> 3 for 0, 1, 2, 3, or more times from the insertion to the removal of colonoscope

    Time frame: From administration until 24 hours after administration

  2. NRS score

    NRS score of resting pain at each time point after the subject is fully awake

    Time frame: From administration until 24 hours after administration

  3. Dose of propofol used

    The total dose used during the induction period, maintenance period, and the entire study process

    Time frame: From the first dose of the study drug to removal of colonoscope on day 1

  4. Success rate of colonoscopy diagnosis and treatment

    The following two conditions must be met for successful diagnosis and treatment: complete colonoscopy diagnosis and treatment and failure to use remedial analgesics

    Time frame: From the first dose of the study drug to removal of colonoscope on day 1

  5. Time to full recovery

    The time from the removal of colonoscope to when the subject opens his/her eyes and can tell his/her date of birth

    Time frame: On day 1

  6. Time to discharge

    The time from the removal of colonoscope to the occurrence of 3 consecutive Aldrete score of ≥ 9

    Time frame: On day 1

  7. The incidence and severity of AEs

    Adverse event/serious adverse event

    Time frame: from signing the informed consent form to the follow-up period

07

Study locations

1 site
  • West China Hospital of Sichuan University
    Chengdu, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in Dec 2020, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2020
First posted
Jul 14, 2020
StartActual
Aug 19, 2020
Primary completionActual
Dec 28, 2020
CompletionActual
Jan 30, 2021
Last update
Feb 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04470128
Responsible party
Sponsor
First posted
Jul 14, 2020
Start date
Aug 19, 2020
Primary completion
Dec 28, 2020
Completion
Jan 30, 2021
Last update
Feb 21, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anrikefon

Start the discussion